OTCMKTS:EMMA Emmaus Life Sciences (EMMA) Stock Price, News & Analysis $0.01 +0.00 (+2.31%) As of 05/27/2025 03:50 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Emmaus Life Sciences Stock (OTCMKTS:EMMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Emmaus Life Sciences alerts:Sign Up Key Stats Today's Range$0.0133▼$0.013350-Day Range$0.01▼$0.0252-Week Range$0.00▼$0.10Volume2,000 shsAverage Volume41,257 shsMarket Capitalization$849,417.80P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEmmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.Read More… Emmaus Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreEMMA MarketRank™: Emmaus Life Sciences scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Emmaus Life Sciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Emmaus Life Sciences is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Emmaus Life Sciences is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the outstanding shares of Emmaus Life Sciences have been sold short.Short Interest Ratio / Days to CoverEmmaus Life Sciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Emmaus Life Sciences has recently decreased by 75.00%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEmmaus Life Sciences does not currently pay a dividend.Dividend GrowthEmmaus Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.00% of the outstanding shares of Emmaus Life Sciences have been sold short.Short Interest Ratio / Days to CoverEmmaus Life Sciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Emmaus Life Sciences has recently decreased by 75.00%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for EMMA on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Emmaus Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders35.00% of the stock of Emmaus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.42% of the stock of Emmaus Life Sciences is held by institutions.Read more about Emmaus Life Sciences' insider trading history. Receive EMMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emmaus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EMMA Stock News HeadlinesEmmaus Life Sciences Reports Quarterly Financial ResultsMay 15, 2025 | prnewswire.comEmmaus Life Sciences IncApril 18, 2025 | uk.investing.comTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?May 28, 2025 | Augusta Precious Metals (Ad)Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi ArabiaJanuary 29, 2025 | finance.yahoo.comEmmaus Life Sciences, Inc.: Emmaus Life Sciences Reports Improved Quarterly Financial ResultsNovember 23, 2024 | finanznachrichten.deEmmaus Life Sciences Reports Improved Quarterly Financial ResultsNovember 19, 2024 | prnewswire.comMike Johnson impersonates Trump: ‘Make it too big to rig’November 7, 2024 | uk.news.yahoo.comQ&A with Madison County candidates for Probate JudgeOctober 31, 2024 | msn.comSee More Headlines EMMA Stock Analysis - Frequently Asked Questions How have EMMA shares performed this year? Emmaus Life Sciences' stock was trading at $0.0085 at the beginning of 2025. Since then, EMMA stock has increased by 56.5% and is now trading at $0.0133. View the best growth stocks for 2025 here. How were Emmaus Life Sciences' earnings last quarter? Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) issued its earnings results on Thursday, May, 15th. The company reported ($0.04) earnings per share (EPS) for the quarter. How do I buy shares of Emmaus Life Sciences? Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Emmaus Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Emmaus Life Sciences investors own include Humanigen (HGEN), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Acasti Pharma (ACST), Actinium Pharmaceuticals (ATNM) and Entasis Therapeutics (ETTX). Company Calendar Last Earnings5/15/2025Today5/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:EMMA CIK822370 Webwww.emmausmedical.com Phone(310) 214-0065Fax866-294-2611Employees60Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.73 million Net Margins-17.11% Pretax MarginN/A Return on EquityN/A Return on Assets-12.66% Debt Debt-to-Equity RatioN/A Current Ratio0.14 Quick Ratio0.12 Sales & Book Value Annual Sales$29.60 million Price / Sales0.03 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares63,866,000Free Float41,513,000Market Cap$849,417.80 OptionableNot Optionable Beta8.37 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:EMMA) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emmaus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emmaus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.